Drug intelligence / Profile preview

MAb-01X-01X

Development stage: Preclinical
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Ophthalmic

Overview

MAb-01X-01X is a monoclonal antibody currently in preclinical development by MedAbome for the treatment of dry age-related macular degeneration (Dry AMD). The therapeutic candidate is designed to target two undisclosed molecular markers associated with the progression of Dry AMD. By utilizing a monoclonal antibody modality, the drug aims to intervene in the pathological processes of retinal degeneration, although the specific mechanism of action and targets have not yet been publicly revealed by the developer.

Beyond the preview

Go deeper on MAb-01X-01X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb-01X-01X.

Explore the full profile